152 related articles for article (PubMed ID: 22363120)
1. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound.
Schirin-Sokhan R; Winograd R; Roderburg C; Bubenzer J; do Ó NC; Guggenberger D; Hecker H; Trautwein C; Tischendorf JJ
World J Gastroenterol; 2012 Feb; 18(6):541-5. PubMed ID: 22363120
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
3. A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
Kitamura H; Koike S; Nakazawa K; Matsumura H; Yokoi K; Nakagawa K; Arai M
J Surg Oncol; 2013 Feb; 107(2):155-9. PubMed ID: 22903532
[TBL] [Abstract][Full Text] [Related]
4. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
[TBL] [Abstract][Full Text] [Related]
5. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
Wu Z; Yang X; Chen L; Wang Z; Shi Y; Mao H; Dai G; Yu X
Medicine (Baltimore); 2017 May; 96(20):e6731. PubMed ID: 28514289
[TBL] [Abstract][Full Text] [Related]
7. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Saiura A
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S390-7. PubMed ID: 24570378
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced ultrasonography in patients with colorectal liver metastases after chemotherapy.
Konopke R; Bunk A; Kersting S
Ultraschall Med; 2008 Sep; 29 Suppl 4():S203-9. PubMed ID: 18833498
[TBL] [Abstract][Full Text] [Related]
10. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of pre-treatment dynamic contrast-enhanced ultrasound for assessing the response of colorectal liver metastases to chemotherapy plus targeted therapy: a dual-institutional study.
Zhou BY; Liu H; Pu YY; Wang LF; Sun YK; Yin HH; Lu D; Ye X; Hu XY; Wang X; Han H; Xia HS; Zhao CK; Xu HX
Abdom Radiol (NY); 2024 Feb; 49(2):414-424. PubMed ID: 37853236
[TBL] [Abstract][Full Text] [Related]
12. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
14. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
15. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
16. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
Goshen E; Davidson T; Zwas ST; Aderka D
Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
[TBL] [Abstract][Full Text] [Related]
17. Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Granata V; Fusco R; Catalano O; Filice S; Amato DM; Nasti G; Avallone A; Izzo F; Petrillo A
PLoS One; 2015; 10(11):e0142876. PubMed ID: 26566221
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
19. Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.
Tranquart F; Dujardin PA; Bouché O; Marcus C; Borg C; Manzoni P; Douillard JY; Labbe-Devilliers C; Terrebonne E; Smith D; Trillaud H; Capitain O; Aubé C; Spano JP; Lucidarme O; Ferru A; Tasu JP; Manfredi S; Bleuzen A; Léger J; Lecomte T
Ultraschall Med; 2018 Oct; 39(5):544-558. PubMed ID: 29232725
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Renin-Angiotensin System Improves Response to Neoadjuvant Therapy in Patients With Liver Metastasis of Colorectal Cancers.
Wirsik NM; Appel PC; Braun A; Strowitzki MJ; Schleussner N; Nienhüser H; Schneider M; Schmidt T
J Surg Res; 2024 Jun; 298():176-184. PubMed ID: 38621351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]